Case number 1:23-cv-00187
Theravance Biopharma R&D IP, LLC et al v. Lupin Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 28, 2023 | 7 | NOTICE of Voluntary Dismissal by Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc. (Bourke, Mary) (Entered: 03/28/2023) (2) |
| Mar 28, 2023 | N/A | CASE CLOSED (ntl) (Entered: 03/28/2023) (0) |
| Mar 28, 2023 | 8 | Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 03/28/2023) (3) |
| Feb 22, 2023 | N/A | Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb) (Entered: 02/22/2023) (0) |
| Feb 21, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris, Inc. for Mylan Ireland Limited, Mylan Specialty L.P. filed by Mylan Ireland Limited, Mylan Specialty L.P.. (Stamoulis, Stamatios) (Entered: 02/21/2023) (2) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Main Document) (23) |
| Feb 17, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 02/21/2023) (3) |
| Feb 17, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/12/2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 5/9/2026. (mpb) (Entered: 02/21/2023) (2) |
| Feb 17, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531. (mpb) (Entered: 02/21/2023) (1) |
| Feb 17, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Theravance Biopharma, Inc. for Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, and Theravance Biopharma US, Inc. filed by Theravance Biopharma Ireland Limited, Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc.. (mpb) (Entered: 02/21/2023) (2) |
| Feb 17, 2023 | N/A | DEFICIENCY NOTICE issued by the Court to Plaintiffs Mylan Ireland Limited and Mylan Specialty L.P.: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (mpb) (Entered: 02/21/2023) (0) |
| Feb 17, 2023 | N/A | No Summons Issued. (mpb) (Entered: 02/21/2023) (0) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Exhibit A) (22) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Exhibit B) (22) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Exhibit C) (23) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Exhibit D) (23) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Exhibit E) (9) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Exhibit F) (26) |
| Feb 17, 2023 | 1 | COMPLAINT filed against Lupin Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4070117.) - filed by Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Specialty L.P., Theravance Biopharma R&D IP, LLC, Mylan Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Civil Cover Sheet)(mpb) (Entered: 02/21/2023) (Civil Cover Sheet) (2) |
